

FREEDOM OF INFORMATION RESPONSE

FOI 3343

Non Small cell carcinoma

1. Within your health trust how many unique patients with Non-small-cell lung carcinoma [Stage IIIB/Stage IV] have been treated in the past 6 months? **We are using an exemption under section 41 of the data protection act as the number is below 5.**

How patients please split by their current drug treatment;

Afatinib (Giotrif) 1
 Ceritinib (Zykadia) 0
 Crizotinib (Xalkori) 0
 Erlotinib (Tarceva) 13
 Gefitinib (Iressa) 6
 Nitendaninb + docetaxel 0
 Pemetrexed (Alimta) 43

Gemcitabine mono 46

or in combination with carboplatin 40 / cisplatin 17

Paclitaxel mono 28

or in combination with carboplatin 30 / cisplatin 0

Doxetaxel mono 67

or in combination with carboplatin 11/ cisplatin 0

Vinorelbine mono 30

or in combination with carboplatin 3 / cisplatin 4

Vincristine mono 5

Or in combination with carboplatin 0/cisplatin 2

Vinblastine mono 3

Or in combinatioin with carboplatin 2/vincristine 0

2. Does your trust carry out EGFR [Epidermal Growth Factor Receptor] tests in house or in a named reference centre ? **These are sent to a named reference centre.**

3. Within your trust how many unique patients with Advanced Prostate Cancer have been treated in the past 6 months? **We do not capture these data so are unable to answer your request.**

How many patients have received in the past 6 months;

Abiraterone (Zytiga) **29**

Cabazitaxel (Jevtana) **18**

Docetaxel (Taxotere) **126**

Enzalutamide (Xtandi) **64**

Radium-223 (Xofigo)

If your trust is unable to identify patients by the condition and treatment, please supply all patients for treatment, regardless of condition.